Abstract
Background/Objective
Pseudohypoparathyroidism (PHP) has a varied presentation, ranging from biochemically detected hypocalcemia in asymptomatic individuals to treatment-refractory seizures. Features may develop over time. Hypocalcemia with recurrent seizures in adolescents indicates a cause other than a primary central nervous system cause, rather than hypoparathyroidism and pseudohypoparathyroidism being the endocrinological causes.
Case Report
We present a case of an adolescent girl with difficult-to-treat seizures and dystonic body movement whose diagnostic workup confirmed PHP. Phenotypically, she fit in Albright hereditary osteodystrophy. However, her hypothyroidism status and obesity are more in favor of PHP type 1a. After treatment with calcium and calcitriol, her symptoms and biochemical parameters improved.
Discussion
PHP is a rare disorder involving hormone resistance that disrupts calcium homeostasis, presenting with hypocalcemia, hyperphosphatemia, and high parathyroid hormone despite normal vitamin D3. Adolescents may solely present with seizures, which poses a diagnostic challenge. The basal ganglia calcification causing extrapyramidal symptoms should prompt evaluation for hypocalcemia and possible endocrine causes. PHP may be associated with Albright Hereditary Osteodystrophy, featuring short stature, obesity, brachydactyly, and low intelligence. PHP requires prompt diagnosis and treatment with calcium and calcitriol, which can fully reverse symptoms.
Conclusion
This case emphasizes the importance of detecting PHP as a potential cause of treatment-refractory seizures in patients with hypocalcemia, underscoring timely management to prevent hypocalcemic complications and seizures.
Key words: seizures, tetany, pseudohypoparathyroidism, basal ganglia calcification
Highlights
-
•
Pseudohypoparathyroidism (PHP) should be considered in adolescents with hypocalcemia and treatment-refractory seizures
-
•
Clinical features such as obesity, round face, and brachydactyly may suggest Albright hereditary osteodystrophy and support a diagnosis of PHP
-
•
Neuroimaging showing basal ganglia calcification is a key indicator and may present with extrapyramidal symptoms like dystonia
-
•
Early endocrine evaluation and biochemical testing are essential for correct diagnosis and avoiding mismanagement with antiepileptic drugs
-
•
Prompt initiation of calcium and calcitriol therapy can reverse symptoms and prevent long-term neurological complications
Clinical Relevance
This case report underscores the importance of recognizing pseudohypoparathyroidism through reviewing history and clinical examinations as a reversible cause of refractory seizures and basal ganglia calcification in children, highlighting the need for prompt endocrine evaluation in such cases.
Introduction
Pseudohypoparathyroidism (PHP) is a rare X-linked dominant or autosomal dominant hereditary disorder (0.79-0.9/100 000) characterized by inadequate response to several hormones, mainly parathyroid hormone (PTH), and phenotypical association, namely Albright hereditary osteodystrophy (AHO).1, 2, 3 However, parathyroid glands are normal or hyperplastic, synthesizing and secreting PTHs in normal amounts.1 It is of 2 types, I and II. Type I is further classified into Ia (most common), Ib, and Ic. The classification is according to genetic defects involving the hormonal receptor adenyl cyclase system: cyclic adenosine monophosphate (cAMP) response to G protein receptor activation.2,4,5
Case Report
An 11.5-year-old girl with a follow-up case of epilepsy presented with recurrent episodes of right-sided focal onset tonic seizures involving the face and neck. She had episodes every 3-4 days for 2 months, with a daily increase in frequency in last 7 days. Each episode lasted 10-15 seconds without impaired consciousness or postictal drowsiness. History of weakness, apathy, and intermittent episodes of paresthesia is present. No history suggestive of meningitis, encephalopathy, or cranial nerve involvement. Her symptoms did not respond to 3 antiepileptics with dose optimization. At the time of presentation, she was on tablet levetiracetam (@40 mg/kg/d), tablet clobazam (15 mg/d), tablet topiramate (@6 mg/kg/d).
With a similar complaint, she was hospitalized at 10 years of age and started on levetiracetam, and she remained seizure-free the following year. Previous electroencephalogram suggested an abnormal waveform consistent with generalized dysrhythmia, though subsequent electroencephalogram (on antiepileptics) was normal. In these 1.5 years, she was once found as vitamin D deficient (17.10 ng/ml). However, clinical or radiological manifestations of rickets, hypocalcemia, or hypomagnesemia were undocumented. She was prescribed calcium and vitamin D3 for 6 weeks. She was born of a nonconsanguineous marriage with an unremarkable birth history. Delayed developmental milestones were documented in all domains, with low-normal intelligence. She attained menarche at 11 years of age, having a regular cycle and no dysmenorrhea. Primary hypothyroidism was diagnosed at 2 months of age, and this is well controlled with levothyroxine (50 mcg/day).
On examination, she had stunting (height 124 cm, height/age <third centile in the Indian Academy of Pediatrics growth chart for girls) and was overweight (body mass index 19.8 kg/m2, using the Indian Academy of Pediatrics growth chart for girls). She has a round face with a depressed nasal bridge, a short neck, and short fourth and fifth toes in bilateral feet (Fig. 1). Her vitals and systemic examination were within normal range. Her recent abnormal movements were found likely to be dystonia rather than seizures. Magnetic resonance imaging brain was suggestive of Wilson's disease or Leigh syndrome, though workups never supported. Dystonia was poorly managed with trihexyphenidyl and tetrabenazine with a continued optimal dosage of antiepileptics. At that time, Chvostek and Trousseau signs were positive. Electrocardiogram showed hypocalcemic changes. Biochemical parameters revealed hypocalcemia (<6 mg/dl [normal 8.8-10.8 mg/dl]), hyperphosphatemia (10.77 mg/dl [normal 3.3-5.4 mg/dl]), and increased intact parathyroid hormone ([139 pg/ml] [12-88 pg/ml]). Renal function test was normal (serum creatinine 0.5 mg/dl, estimated glomerular filtration rate according to the modified Schwartz formula was 102.42 ml/min/1.73 m2). Noncontrast computed tomography head showed calcification at basal ganglia (Fig. 2). She was managed with injectable calcium gluconate bolus, then continuous infusion till clinical and biochemical improvement; followed by oral calcium (2 gm/day in four divided doses) and calcitriol (0.5 mcg twice a day). All antiepileptics, trihexyphenidyl, and tetrabenazine were discontinued. Gradually, all symptoms subsided. Evaluation also revealed bilateral brachydactyly involving fourth and fifth metatarsals on x-ray. According to clinical features, a syndromic association of AHO was suspected. Financial constraints hindered genetic analysis.
Fig. 1.
Phenotype of the patient. A, Round face with a depressed nasal bridge and a short neck. B, Brachydactyly in the fourth and fifth toes in bilateral feet.
Fig. 2.
NCCT head showing basal ganglia calcification (yellow arrow). NCCT = noncontrast computed tomography.
Discussion
Vitamin D3, PTH, and calcitonin maintain calcium homeostasis in the body with agonist-antagonistic action of each other on the gut, kidney, and bone.5,6 In PHP, hormone resistance and clinical characteristics may evolve over time.7 Biochemically, hypocalcemia, hyperphosphatemia, normal vitamin D3, and increased PTH level are expected. PHP manifests variedly, among which tetany, carpopedal spasm, paresthesia, and tingling sensation over limbs are the most common and consistent, though it may present with persistent seizures or dysrhythmia. Hypocalcemic seizures may be the sole manifestation in adolescents. Phenotypically, AHO association may be found.1,3,8 PHP is divided into 2 main types: PHP-I and PHP-II. In PHP-I, the nephrogenous cAMP generation and phosphate urinary excretion after exogenous PTH administration are low in comparison to the healthy population. PHP Ib is caused by epigenetic changes at differentially methylated regions within guanine nucleotide binding protein, alpha stimulating activity polypeptide, resulting in end-organ resistance to biological effects of PTH, predominantly with no dysmorphic features. The features, including short, stocky build, obesity, round face, short neck, brachydactyly with short and broad phalanges, and low-normal intelligence, are primarily associated with type Ia and Ic, along with multihormone resistance. Despite type Ia and type Ic being similar, type Ic has normal erythrocyte Gsα activity. In PHP-II, cAMP generation in the kidney is normal, but the urinary excretion of phosphate is decreased.9 Congenital hypothyroidism can be the earliest presentation.3 Late manifestations are related to metastatic calcification due to chronic deposition of calcium-phosphorus complex, involving bone and subcutaneous tissue forming exostoses and calcinosis cutis, basal ganglia calcification (up to 50%), and lenticular cataract.3,7,8 Basal ganglia involvement leads to dystonia, spasticity, tremor, and Parkinson-like features.7 Genetic analysis helps to determine the specific type for genetic counseling. PHP, in our case, associated with hypothyroidism, increases the probability of PHP 1a.1 Pseudopseudohypoparathyroidism (PPHP) may develop independently or in PHP families and exhibits as AHO features without PTH resistance.9 Recently, “inactivating PTH/PTHrP signaling disorder” (iPPSD) terminology has been proposed to classify all disorders with defects in PTH and/or PTHrP cAMP-mediated pathway. It unifies clinical characteristics and molecular and genetic data; however, a confirmed genetic defect is not required. According to this classification, PHP Type I, II, and PPHP will be under the iPPSD group in the absence of genetic information. With Gsa-inactivating mutation, PHP type Ia, Ic, PPHP, AHO will be classified as iPPSD2, while PHP1b will be classified as iPPSD3; this is due to methylation changes at guanine nucleotide binding protein alpha stimulating activity polypeptide.9 Management of PHP-associated extrapyramidal signs is entirely different from idiopathic Parkinson's disease. PHP requires treatment with calcitriol and associated documentation or symptomatic hypocalcemia to be managed with calcium supplementation, aiming to achieve normal calcium and phosphorus levels and maintain PTH within a normal range.1 While treating patients with calcium and calcitriol, urinary calcium and creatinine should be monitored (U-Ca/U-creatinine index) to prevent hypercalciuria/urolithiasis/nephrocalcinosis. Prompt management completely reverses the symptoms. The index case was previously misdiagnosed as a seizure disorder and mismanaged. Her poorly controlled symptoms, new-onset extrapyramidal features, and basal ganglia calcification demanded endocrinological evaluation. Biochemical abnormalities and endocrinological assessment confirmed the diagnosis and improved drastically on treatment.
Conclusion
PHP is a rare hereditary, disabling disorder. Their heterogeneous manifestations often challenge early diagnosis. Typical clinical findings alongside biochemical parameters and neuroimaging play the key roles to recognize. Prompt treatment is necessary to manage symptoms and complications.
Author Contributions
R.M. contributed to data extraction and drafted the manuscript. A.D. drafted the manuscript. All authors contributed to the preparation and revision of the manuscript.
Ethical Consideration
Written informed consent and assent were obtained from the parent and the patient for publication of the manuscript and the figures.
Disclosure
The authors have no conflicts of interest to disclose.
References
- 1.Mantovani G. Clinical review: pseudohypoparathyroidism: diagnosis and treatment. J Clin Endocrinol Metab. 2011;96(10):3020–3030. doi: 10.1210/jc.2011-1048. [DOI] [PubMed] [Google Scholar]
- 2.Mantovani G., Spada A., Elli F.M. Pseudohypoparathyroidism and Gsα-cAMP-linked disorders: current view and open issues. Nat Rev Endocrinol. 2016;12(6):347–356. doi: 10.1038/nrendo.2016.523. [DOI] [PubMed] [Google Scholar]
- 3.Ludar H., Levy-Shraga Y., Admoni O., et al. Clinical and molecular characteristics and long-term Follow-up of children with pseudohypoparathyroidism type IA. J Clin Endocrinol Metab. 2024;109(2):424–438. doi: 10.1210/clinem/dgad5244. [DOI] [PubMed] [Google Scholar]
- 4.Navaeifar M.R., Zamanfar D. Calcification of soft tissues in a family, case report and review of pseudohypoparathyroidism. J Rare Disord Diagn Ther. 2017;3:16. doi: 10.21767/2380-7245.100169. [DOI] [Google Scholar]
- 5.Jüppner H. Genetic and epigenetic defects at the GNAS locus cause different forms of pseudohypoparathyroidism. Ann Endocrinol (Paris) 2015;76(2):92–97. doi: 10.1016/j.ando.2015.03.0116. [DOI] [PubMed] [Google Scholar]
- 6.Poole K.E., Reeve J. Parathyroid hormone - a bone anabolic and catabolic agent. Curr Opin Pharmacol. 2005;5(6):612–617. doi: 10.1016/j.coph.2005.07.0047. [DOI] [PubMed] [Google Scholar]
- 7.Koller W.C., Cochran J.W., Klawans H.L. Calcification of the basal ganglia: computerized tomography and clinical correlation. Neurology. 1979;29(3):328–333. doi: 10.1212/wnl.29.3.328. [DOI] [PubMed] [Google Scholar]
- 8.Mazoni L., Saponaro F., Apicella M., Mantovani, et al. Prevalence of basal ganglia calcification in patients with pseudohypoparathyroidism. Endocr Abstr. 2018;56 doi: 10.1530/endoabs.56.P239. [DOI] [Google Scholar]
- 9.Thiele S., Mantovani G., Barlier A., et al. From pseudohypoparathyroidism to inactivating PTH/PTHrP signalling disorder (iPPSD), a novel classification proposed by the EuroPHP network. Eur J Endocrinol. 2016;175(6):P1–P17. doi: 10.1530/EJE-16-0107. [DOI] [PubMed] [Google Scholar]


